Tersus Life Sciences LLC, founded in 2011 & located in Bonita Springs, FL, is a US based bio-life science company dedicated to the research, development and commercialization of Provinal®, a naturally occurring highly purified monounsaturated fatty acid of the C16:1n7 palmitoleic class. Initially, Provinal® has demonstrated a broad range of indications and applications by its lipid-lowering and anti-inflammatory effects in the management of cardiometabolic disorders, glucose metabolism and eye and tear health, bridging the treatment gap in lipid management.
In preclinical, clinical and human epidemiological studies, Provinal® has shown anti-inflammatory and lipid-lowering benefits linked to the prevention of metabolic syndrome, including cardiovascular disease, HDL augmentation, prevention/regression of atherosclerotic plaque, adjunctive insulin resistance therapy associated with Type II diabetes, obesity and dry eye disease associated with Meibomian gland dysfunction and poor tear production and quality. Under the trademarked name Provinal®, Tersus has secured composition-of-matter and specific methods-of-use patents and patents-pending, worldwide, and will continue to do so as research continues. Raw material as a natural source, is plentiful and readily available for purification, fractionization and distillation for a variety of potency formulation, stand-alone products and efficacious combination products. To Tersus’ knowledge, there is no competitive product on the market or under development, nor are there other fatty acid products that possess such a broad range of pharmacological activity and potential, both GRAS and NDI certified.
Tersus’ business model for the marketing and sale of Provinal® is focused on the commercialization and sale of Provinal® to strategic market-specific global industrial partners, the appropriate brokers, distributors and market and category-leading branding companies in North America, regions of Europe, Asia and Australia, Canada and South America.